Long-term Continuation Rates

A recently published article in the Lancet compares the long-term continuation rates of VNS Therapy with the continuation rates of several of the newer AEDs, including levetiracetam. This comparison demonstrates that long-term continuation rates with VNS Therapy are remarkably better than long-term continuation rates with other treatments for pharmacoresistant epilepsy. After 3 years, approximately 72% of patients choose to continue with VNS Therapy whereas approximately 70% of patients discontinue their drug therapy.¹

¹Ben-Menachem E et al. Lancet. 2002; 1:477-482.



For more information on the VNS Therapy for pharmacoresistant epilepsy please contact us or visit the Cyberonics website.